Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research report released on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Performance

NASDAQ SRNE opened at $0.02 on Friday. Sorrento Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.42. The company has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.05.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.